The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
immune checkpoint inhibitors
neoadjuvant treatment
non‐small‐cell lung cancer
Journal
Chronic diseases and translational medicine
ISSN: 2589-0514
Titre abrégé: Chronic Dis Transl Med
Pays: United States
ID NLM: 101679934
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
14
09
2021
accepted:
19
01
2022
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
2
7
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and locally advanced non-small-cell lung cancer (NSCLC). Antibodies blocking inhibitory immune checkpoints, such as programmed death 1 (PD-1) and its ligand (PD-L1), have remarkable antitumor efficacy and have been approved as a standard first- or second-line treatment in non-oncogene-addicted advanced NSCLC. The successful application of immunotherapy in advanced lung cancer has motivated researchers to further evaluate its clinical role as a neoadjuvant setting for resectable NSCLC and for improved long-term overall survival and curative rates. In this review, we discuss the efforts that incorporate ICIs into the treatment paradigm for surgically resectable lung cancer. We reviewed the early-phase results from neoadjuvant clinical trials, the landscape of the majority of ongoing phase III trials, and discuss the prospects of ICIs as a curative therapy for resectable lung cancer. We also summarized the potential biomarkers and beneficiaries involved in the current study, as well as the remaining unresolved challenges for neoadjuvant immunotherapy.
Identifiants
pubmed: 35774424
doi: 10.1002/cdt3.19
pii: CDT319
pmc: PMC9215714
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100-111Informations de copyright
© 2022 The Authors. Chronic Diseases and Translational Medicine published by John Wiley & Sons, Ltd on behalf of Chinese Medical Association.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
J Clin Oncol. 2019 Sep 1;37(25):2235-2245
pubmed: 31194613
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Lancet Oncol. 2021 Jun;22(6):824-835
pubmed: 34015311
J Thorac Oncol. 2012 May;7(5):825-32
pubmed: 22481232
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Ann Oncol. 2018 Aug 1;29(8):1853-1860
pubmed: 29982279
J Clin Oncol. 2002 Jan 1;20(1):247-53
pubmed: 11773176
Lancet Oncol. 2020 Jun;21(6):786-795
pubmed: 32386568
J Thorac Oncol. 2012 May;7(5):841-9
pubmed: 22722786
Nature. 2021 Aug;596(7870):126-132
pubmed: 34290408
J Clin Oncol. 2021 Sep 10;39(26):2872-2880
pubmed: 34251873
Cancer J. 2020 Nov/Dec;26(6):543-547
pubmed: 33298726
Lancet. 2015 Sep 12;386(9998):1049-56
pubmed: 26275735
Eur J Cardiothorac Surg. 2003 Feb;23(2):229-32
pubmed: 12559347
Target Oncol. 2021 Jul;16(4):425-434
pubmed: 33983556
J Thorac Oncol. 2019 Jan;14(1):124-129
pubmed: 30138764
Oncoimmunology. 2019 Mar 1;8(5):e1581530
pubmed: 31069141
Eur J Cardiothorac Surg. 2021 Jul 14;60(1):81-88
pubmed: 33661301
ESMO Open. 2021 Oct;6(5):100244
pubmed: 34479033
J Thorac Cardiovasc Surg. 2022 Feb;163(2):427-436
pubmed: 33985811
Nat Med. 2018 Nov;24(11):1645-1648
pubmed: 30401867
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nucl Med Commun. 2019 Aug;40(8):802-807
pubmed: 31045745
Lancet Oncol. 2014 Jan;15(1):e42-50
pubmed: 24384493
Lancet Oncol. 2020 Nov;21(11):1413-1422
pubmed: 32979984
Nat Commun. 2021 Aug 19;12(1):5045
pubmed: 34413300
Nat Med. 2021 Mar;27(3):504-514
pubmed: 33603241
Lancet. 2014 May 3;383(9928):1561-71
pubmed: 24576776
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
Lung Cancer. 2020 Sep;147:143-153
pubmed: 32717571
J Thorac Oncol. 2011 Sep;6(9):1530-6
pubmed: 21792074
Lung Cancer. 2003 Oct;42(1):69-77
pubmed: 14512190
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Thorac Oncol. 2020 May;15(5):816-826
pubmed: 32036071
J Thorac Oncol. 2013 Aug;8(8):1084-90
pubmed: 23857398
Front Oncol. 2020 Oct 09;10:575472
pubmed: 33163406
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Clin Oncol. 2003 May 1;21(9):1752-9
pubmed: 12721251
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593